Full Name
Dr. Jae Park MD
Job Title
Chief, Cellular Therapy Service/ Department of Medicine
Company/Affiliation
Memorial Sloan Kettering Cancer Center
Speaker Bio
Jae Park, MD is a Full Member and Attending Physician in the Division of Hematologic Oncology, Chief of Cellular Therapy Service, and a Director of Adult Acute Lymphoblastic Leukemia Program at Memorial Sloan Kettering Cancer Center (MSK) in New York City, New York.
Dr. Park received his medical degree from the Johns Hopkins School of Medicine and completed an internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center.
Dr. Park has written over 100 peer-reviewed articles appearing in New England Journal Medicine, Blood, Cancer Discovery and Journal of Clinical Oncology. His research is focused on developing effective and safe targeted and immunotherapies for patients with hematologic malignancies and conducting translational studies that will enhance our understanding of the current therapeutics and inform future clinical studies, with an ultimate goal to cure more patients with improved treatment experience.
To this end, he has successfully opened over 15 investigator-initiated therapeutic trials in the field of hematologic malignancies and cellular therapy with accompanying translational studies and grant supports from American Society of Hematology (ASH), Leukemia and Lymphoma Society (LLS), American Society of Clinical Oncology (ASCO), American Association of Clinical Research (AACR), Geoffrey Beene Research Foundation, and NCCN.
He is widely recognized as one of the world experts in the field of CAR T cell therapies and ALL and is the leading principal investigator of several clinical trials in patients with ALL and CLL/NHL using CAR T, NK cell therapies, BiTEs, IDCs, targeted agents, and immunomodulators.
Jae Park, MD is a Full Member and Attending Physician in the Division of Hematologic Oncology, Chief of Cellular Therapy Service, and a Director of Adult Acute Lymphoblastic Leukemia Program at Memorial Sloan Kettering Cancer Center (MSK) in New York City, New York.
Dr. Park has written over 100 peer-reviewed articles appearing in New England Journal of Medicine, Lancet, Nature Medicine, Science Translational Medicine, Blood, Cancer Discovery and Journal of Clinical Oncology.
His research has been recognized and funded by the ASH, AACR, ASCO, Leukemia and Lymphoma Society, Geoffrey Beene Research Foundation, and NCCN.
As a chief for cell therapy service, Dr. Park oversees clinical care and drug development of immune effector cell (IEC) therapies for both hematologic and solid tumor malignancies and provides education for all faculties, fellows, nurses and pharmacists.
His research focus is to translate and establish novel targeted and immunotherapies to cure more patients with cancer.
He is widely recognized as one of the world 4 experts in the field of CAR T cell therapies and ALL and is the leading principal investigator of several clinical trials in patients with ALL and CLL/NHL using CAR T, NK cell therapies, BiTEs, IDCs, targeted agents, and immunomodulators.
Dr. Park received his medical degree from the Johns Hopkins School of Medicine and completed an internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center.
Dr. Park has written over 100 peer-reviewed articles appearing in New England Journal Medicine, Blood, Cancer Discovery and Journal of Clinical Oncology. His research is focused on developing effective and safe targeted and immunotherapies for patients with hematologic malignancies and conducting translational studies that will enhance our understanding of the current therapeutics and inform future clinical studies, with an ultimate goal to cure more patients with improved treatment experience.
To this end, he has successfully opened over 15 investigator-initiated therapeutic trials in the field of hematologic malignancies and cellular therapy with accompanying translational studies and grant supports from American Society of Hematology (ASH), Leukemia and Lymphoma Society (LLS), American Society of Clinical Oncology (ASCO), American Association of Clinical Research (AACR), Geoffrey Beene Research Foundation, and NCCN.
He is widely recognized as one of the world experts in the field of CAR T cell therapies and ALL and is the leading principal investigator of several clinical trials in patients with ALL and CLL/NHL using CAR T, NK cell therapies, BiTEs, IDCs, targeted agents, and immunomodulators.
Jae Park, MD is a Full Member and Attending Physician in the Division of Hematologic Oncology, Chief of Cellular Therapy Service, and a Director of Adult Acute Lymphoblastic Leukemia Program at Memorial Sloan Kettering Cancer Center (MSK) in New York City, New York.
Dr. Park has written over 100 peer-reviewed articles appearing in New England Journal of Medicine, Lancet, Nature Medicine, Science Translational Medicine, Blood, Cancer Discovery and Journal of Clinical Oncology.
His research has been recognized and funded by the ASH, AACR, ASCO, Leukemia and Lymphoma Society, Geoffrey Beene Research Foundation, and NCCN.
As a chief for cell therapy service, Dr. Park oversees clinical care and drug development of immune effector cell (IEC) therapies for both hematologic and solid tumor malignancies and provides education for all faculties, fellows, nurses and pharmacists.
His research focus is to translate and establish novel targeted and immunotherapies to cure more patients with cancer.
He is widely recognized as one of the world 4 experts in the field of CAR T cell therapies and ALL and is the leading principal investigator of several clinical trials in patients with ALL and CLL/NHL using CAR T, NK cell therapies, BiTEs, IDCs, targeted agents, and immunomodulators.
Speaking At
